Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patient

Grants and Contracts Details

StatusActive
Effective start/end date4/4/22 → 1/29/25

Funding

  • BeiGene Switzerland GmbH: $110,117.00